Thompson Siegel & Walmsley’s Sarepta Therapeutics SRPT Stock Holding History

Thompson Siegel & Walmsley’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-752	Closed	-$73K	–	507
2023 Q4	$73K	Hold	752	–	–	﹤0.01%	404
2023 Q3	$91K	Hold	752	–	–	﹤0.01%	388
2023 Q2	$86K	Hold	752	–	–	﹤0.01%	401
2023 Q1	$104K	Hold	752	–	–	﹤0.01%	393
2022 Q4	$97K	Hold	752	–	–	﹤0.01%	389
2022 Q3	$83K	Hold	752	–	–	﹤0.01%	396
2022 Q2	$56K	Hold	752	–	–	﹤0.01%	407
2022 Q1	$59K	Hold	752	–	–	﹤0.01%	451
2021 Q4	$68K	Hold	752	–	–	﹤0.01%	461
2021 Q3	$70K	Sell	752 -248	-25%	-$19.1K	﹤0.01%	451
2021 Q2	$78K	Hold	1,000	–	–	﹤0.01%	452
2021 Q1	$75K	Hold	1,000	–	–	﹤0.01%	437
2020 Q4	$170K	Hold	1,000	–	–	﹤0.01%	345
2020 Q3	$140K	Hold	1,000	–	–	﹤0.01%	346
2020 Q2	$160K	Hold	1,000	–	–	﹤0.01%	341
2020 Q1	$98K	Hold	1,000	–	–	﹤0.01%	360
2019 Q4	$129K	Buy	+1,000	New	+$101K	﹤0.01%	407

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Thompson Siegel & Walmsley's SRPT Position: Q1 2024 in Review

Thompson Siegel & Walmsley sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 752 shares — an estimated $73K sold.

Thompson Siegel & Walmsley first reported a position in SRPT in Q4 2019 and held it in 17 quarters. The position peaked at $170K in Q4 2020. 415 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

Thompson Siegel & Walmsley reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
Thompson Siegel & Walmsley sold 752 Sarepta Therapeutics shares in Q1 2024, an estimated $73K.
Thompson Siegel & Walmsley first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 17 quarters.
Thompson Siegel & Walmsley's Sarepta Therapeutics position peaked at $170K in Q4 2020.
415 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2024, filed 9 May 2024.